About: Javamide-II Inhibits IL-6 without Significant Impact on TNF-alpha and IL-1beta in Macrophage-Like Cells

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Javamide-II Inhibits IL-6 without Significant Impact on TNF-alpha and IL-1beta in Macrophage-Like Cells Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Javamide-II Inhibits IL-6 without Significant Impact on TNF-alpha and IL-1beta in Macrophage-Like Cells
Creator	Park, Jae Wang, Thomas Peters, Renee Pham, Quynhchi
Source	Medline; PMC
abstract	The main aim of this study is to find a therapeutic compound to inhibit IL-6, not TNF-alpha and IL-1beta, in macrophage-like cells, because the high-levels of IL-6 production by macrophages are reported to cause unfavorable outcomes under several disease conditions (e.g., autoimmune diseases, and acute viral infections, including COVID-19). In this study, the potential effects of javamide-II on IL-6, IL-1beta and TNF-alpha productions were determined using their ELISA kits in macrophage-like THP-1 cells. Western blots were also performed using the same cells, to determine its effects on signaling pathways (ERK, p38, JNK, c-Fos, ATF-2, c-Jun and NF-κB p65). At concentrations of 0.2–40 µM, javamide-II inhibited IL-6 production significantly in the THP-1 cells (IC(50) of 0.8 µM) (P < 0.02). However, javamide-II did not inhibit IL-1beta or TNF-alpha productions much at the same concentrations. In addition, the treatment of javamide-II decreased the phosphorylation of p38 without significant effects on ERK and JNK phosphorylations in the THP-1 cells. Furthermore, the p38 inhibition, followed by the reduction of ATF-2 phosphorylation (not c-Fos, c-Jun or NF-κB p65), led to the suppression of IL-6 mRNA expression in the cells (P < 0.02). The data indicate that javamide-II may be a potent compound to inhibit IL-6 production via suppressing the p38 signal pathway, without significant effects on the productions of TNF-alpha and IL-1beta in macrophage-like THP-1 cells.
has issue date	2020-05-29(xsd:dateTime)
bibo:doi	10.3390/biomedicines8060138
bibo:pmid	32485858
has license	cc-by
sha1sum (hex)	2fff5f3b5d34872d2853570feac8af367a79b9e6
schema:url	https://doi.org/10.3390/biomedicines8060138
resource representing a document's title	Javamide-II Inhibits IL-6 without Significant Impact on TNF-alpha and IL-1beta in Macrophage-Like Cells
has PubMed Central identifier	PMC7344767
has PubMed identifier	32485858
schema:publication	Biomedicines
resource representing a document's body	covid:2fff5f3b5d34872d2853570feac8af367a79b9e6#body_text
is schema:about of	named entity 'aim' named entity 'TNF-alpha' named entity 'viral infections' named entity 'cells' named entity 'cells' named entity 'signal' named entity 'led' named entity 'determined' named entity 'cells' named entity 'IL-6' named entity 'TNF-alpha' named entity 'performed' named entity 'IL-6' named entity 'potent' named entity 'inhibition' named entity 'study' named entity 'Cells' named entity 'INCLUDING' named entity 'P65' named entity 'MUCH' named entity 'ERK' named entity 'ELISA' named entity 'ITS' named entity 'EFFECTS' named entity 'effects' named entity 'p38' named entity 'reduction' named entity 'inhibit' named entity 'c-Fos' named entity 'concentrations' named entity 'TNF-alpha' named entity 'cells' named entity 'p38' named entity 'phosphorylation' named entity 'p65' named entity 'c-Fos' named entity 'NF-κB' named entity 'c-Fos' named entity 'autoimmune diseases' named entity 'mRNA expression' named entity 'ATF-2' named entity 'c-Jun' named entity 'p38' named entity 'THP-1' named entity 'macrophage' named entity 'IL-1beta' named entity 'Significant Impact' named entity 'IL-1beta' named entity 'RNA' named entity 'THP-1' named entity 'THP-1 cells' named entity 'JNK' named entity 'liver diseases' named entity 'p38' named entity 'transcriptional factor' named entity 'TNF-alpha' named entity 'Chicago' named entity 'mRNA' named entity 'ATF-2' named entity 'IL-6' named entity 'NF-κB' named entity 'p38' named entity 'IL-6' named entity 'USDA' named entity 'LPS' named entity 'phosphorylation' named entity 'transcription factor' named entity 'ATF-2' named entity 'THP-1' named entity 'Tryptophan' named entity 'mmol' named entity 'metabolic functions' named entity 'High Performance Liquid Chromatography' named entity 'IL-6' named entity 'p65' named entity 'IL-6' named entity 'ATF-2' named entity 'NF-κB'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software